News

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Pomdoctor (NASDAQ:POM) stock moved upwards by 115.1% to $1.43 during Wednesday's regular session. The market value of their outstanding shares is at $4.9 million. Stablecoin Development (AMEX:SDEV) stock

Benzinga·09:05

GT Biopharma Files Prospectus Related To The Offer Up To 13,502,835 Shares Of Common Stock By Selling Stockholders

-SEC Filing

Benzinga·13:32

EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy

GT Biopharma, Inc. on Tuesday secured IND clearance from the U.S. Food and Drug Administration (FDA) to evaluate its novel therapeutic candidate, GTB-5550, in treating multiple myeloma. Multiple myeloma is a rare type of blood cancer that develops in the...

Yahoo·07:30

Let's uncover which stocks are experiencing notable gaps during today's session.

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

ChartMill·10:30

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026 Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway

Yahoo·09:15

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $22.3 million. DataMEDS AI (NASDAQ:MEDS) shares increased by

GT Biopharma Announces IND Clearance From FDA For GTB-5550 In Multiple Myeloma

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocolInitiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant

Benzinga·05:16

EXCLUSIVE: GT Biopharma Announces Potential New Indication for GTB-5550, A B7-H3-Targeted Natural Killer Cell Engager, For Multiple Myeloma; FDA Clearance Under Investigator Sponsored Trial Protocol

FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocolInitiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant

Benzinga·04:45

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday's regular session. Scinai Immunotherapeutics (NASDAQ:SCNI) stock increased by 45.18% to $2.41. The company's

Benzinga·09:06

Top movers in Friday's session

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

ChartMill·15:00

GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript

GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy September 11, 2026 2:00 PM EDTCompany...

SeekingAlpha·14:57GTBP▲+9.9%